INO - Inovio Pharmaceuticals - A NYSE Small-Cap Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INO - Inovio Pharmaceuticals - A NYSE Small-Cap

INO 2.250

+4.7%

Dec 24 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lynn	7/13/2018 12:32:09 PM
	of 67

From the end of June: Inovio Pharma announced positive Phase 1 data for vaccine treatment of Middle East Respiratory Syndrome 8:05 AM ET, 06/27/2018 - Briefing.com The drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants.Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing. Dr. Joel Maslow, GeneOne's Chief Medical Officer, presented the data Tuesday this week in Seoul, Korea at the WHO-IVI Joint Symposium for MERS-CoV Vaccine Development.In collaboration with GeneOne Life Science, Inovio plans to begin a Phase 1/2 study for MERS in the third quarter of this year. The study will be conducted by GeneOne Life Science in Korea and fully funded by a $34 mln grant from the Samsung Foundation through the International Vaccine Institute. [Copy/paste news from brokerage account]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next